Show simple item record

dc.contributor.authorAllanson, Emma R
dc.contributor.authorPeng, Yang
dc.contributor.authorChoi, Angela
dc.contributor.authorHayes, Sandra
dc.contributor.authorJanda, Monika
dc.contributor.authorObermair, Andreas
dc.date.accessioned2020-08-17T00:56:31Z
dc.date.available2020-08-17T00:56:31Z
dc.date.issued2020
dc.identifier.issn1525-1438
dc.identifier.doi10.1136/ijgc-2020-001678
dc.identifier.urihttp://hdl.handle.net/10072/396445
dc.description.abstractINTRODUCTION: Sarcopenia is a condition described as the progressive generalized loss of muscle mass and strength. While sarcopenia has been linked with poorer outcomes following a variety of malignancies, its relationship with all gynecological cancer clinical outcomes has, to date, not been evaluated. This review interrogates the concept of sarcopenia as a prognostic tool for oncological outcomes and adverse effects of treatments in all primary gynecological malignancies. METHODS: This systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines, searching PubMed, Embase, and CINAHL without date or language restriction for studies reporting on sarcopenia and gynecological malignancies. Random effects meta-analysis models were used to determine the effects of sarcopenia on progression-free survival, overall survival, and treatment-related adverse events. RESULTS: Data were analyzed from 13 studies, including 2446 patients (range 60-323) with ovarian cancer (n=1381), endometrial cancer (n=354), or cervical cancer (n=481). Sarcopenia was associated with lower progression-free survival (HR 1.69, 95% CI 1.03 to 2.76), overall survival (HR 1.33, 95% CI 1.08 to 1.64), and no increase in adverse events (HR 1.28, 95% CI 0.69 to 2.40). The risk of bias of the studies was mostly rated unclear, and Begg's and Egger's test revealed a potential publication bias for progression-free survival and overall survval, although the HRs remained significant when adjusting for it. CONCLUSION: Sarcopenia is associated with worse progression-free survival and overall survival in gynecological oncology malignancies. Further research is warranted to validate these findings in larger and prospective samples using standardized methodology and to examine if an intervention could reverse its effect in gynecological oncology trials.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherBMJ
dc.relation.ispartofjournalInternational Journal of Gynecologic Cancer
dc.subject.fieldofresearchOncology and Carcinogenesis
dc.subject.fieldofresearchcode1112
dc.subject.keywordsCervix Uteri
dc.subject.keywordsEndometrial Neoplasms
dc.subject.keywordsOvarian Cancer
dc.titleA systematic review and meta-analysis of sarcopenia as a prognostic factor in gynecological malignancy
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationAllanson, ER; Peng, Y; Choi, A; Hayes, S; Janda, M; Obermair, A, A systematic review and meta-analysis of sarcopenia as a prognostic factor in gynecological malignancy, International Journal of Gynecologic Cancer, 2020
dcterms.dateAccepted2020-07-06
dc.date.updated2020-08-12T01:10:17Z
dc.description.versionAccepted Manuscript (AM)
gro.description.notepublicThis publication has been entered in Griffith Research Online as an advanced online version.
gro.rights.copyright© The Author(s) 2020. This is the author-manuscript version of this paper. It is posted here with permission of the copyright owner(s) for your personal use only. No further distribution permitted. For information about this journal please refer to the publisher’s website or contact the author(s).
gro.hasfulltextFull Text
gro.griffith.authorHayes, Sandi C.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record